PFE - Pfizer Inc
A pharmaceutical heavyweight known for COVID-19 vaccines and treatments, now working to rebuild growth momentum through oncology acquisitions and pipeline diversification.
Finlify Score
51.7 / 100
Data Quality
PARTIAL
Penalty
-1.0
Sector
Health Care
Close Price
$24.91
-0.95%
52W Range
$23.11 - $28.75
Market Cap
$137.2B
-1.0%Compared to previous day
2026 Q1 Revenue
$12.1B
+133.1%Changes from last reporting quarter
2026 Q1 EPS
$0.00
Diluted shares
Analyst Rating
36 analysts in latest ratings feed
RSI
59.6
40-70 moderate
2Y Range Position
38%
-20.5% from high / +19.1% from low
Beta
0.28
Relative to market benchmark
MACD
0.09
MACD line 0.02 / signal line -0.07
Fundamental Trend
Growth 73.8Financial Health
Quality 85.8Data Quality
PARTIALValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD51.7 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $12.1B+133.1% | -$36.5B-354.5% | $14.4B+16.0% | $12.4B+6.7% |
| Gross Profit | - | - | - | - |
| Operating Income | - | - | - | - |
| Net Income | $2.7B+263.0% | -$1.6B-146.5% | $3.5B+21.7% | $2.9B-1.9% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
Finlify's quantitative signal for PFE as of 2026-07-23 is HOLD, with a Finlify Score of 53.7 out of 100. This score appears to be influenced by strong fundamental and financial quality metrics, partially offset by lower relative strength and a deduction for partial data quality.
Technical
The asset's Relative Strength appears low at 19.6/100, which may suggest underperformance compared to its peers. While Accumulation / Volume is moderate at 51.5/100 and the RSI(14) is near neutral at 53.0, the 60-day return of -6.6% and a -12.4% distance from its 52-week high could indicate some recent downward pressure, despite a 4.0% 20-day return.
Fundamentals
PFE exhibits a strong Fundamental Trend score of 73.8/100 and excellent Financial Quality at 85.8/100, which may suggest a robust underlying business. Its valuation metrics include a P/E of 18.1x, P/B of 1.6x, and P/S of 2.2x, alongside a notable dividend yield of 6.88%. The low Beta of 0.3 could indicate lower volatility relative to the broader market.
Macro Context
The current macro environment, characterized by elevated inflation (CPI YoY at 3.7%, Core PCE YoY at 3.4%) and a positive yield spread (10Y-2Y at 0.4%), may influence PFE's operational costs and borrowing environment. A 4.2% unemployment rate could suggest a stable consumer base for pharmaceutical products.
Key Risks
- Partial data quality, including the use of an EPS proxy, resulted in a -1.0 deduction to the Finlify Score and may limit the comprehensiveness of the analysis.
- The low Relative Strength (19.6/100) and a negative 60-day return (-6.6%) could suggest recent underperformance that may persist.
- Upcoming earnings on 2026-08-04 present an event risk that could lead to significant price volatility.